Organization | National Center for Tuberculosis Problems, Kazakhstan

National Center for Tuberculosis Problems, Kazakhstan Report issue

Government Phase 1 Phase 3

Organization Overview

First Clinical Trial

2013

NCT02501421

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (7)

bedaquiline (sirturo) (1 trial)

clofazimine (lamprene) (1 trial)

delamanid (1 trial)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (1 trial)

moxifloxacin (avelox) (1 trial)

pyrazinamide (Aldinamide) (1 trial)

Drugs in Phase 1 Trials (2)

tb/flu-01l (1 trial)

Tuberculin, Purified Protein Derivative (Tubersol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Bacterial Infections (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 9